Background {#Sec1}
==========

Necrotizing enterocolitis (NEC), which is one of the most devastating neonatal diseases, has become a priority for research \[[@CR1]\]. Despite great advances in neonatal care, the morbidity, mortality and health-care costs directly related to the disease are substantial: during hospital stay, the economic burden of NEC in the United States has been estimated as high as several billions USD per year, which is approximately 20 % of the costs for Neonatal Intensive Care Units in the country; furthermore, this estimate is likely to be much higher when the costs of long-term care of survivors are taken into account \[[@CR2]\].

NEC is a multifactorial disease: prematurity is a well-recognized risk factor, and approximately 90 % of the infants who develop NEC are born preterm \[[@CR3]\]. This is probably due to specific comorbidities of prematurity, such as immunodeficiency, use of broad-spectrum antimicrobials, delayed enteral feeding and low availability of human milk.

Recently, research has focused on the role of gut microbiota and its manipulations, such as the use of probiotics, on disease and health status. Probiotics are live--microorganisms which, when ingested in adequate amounts, confer a health-benefit to the host through an interaction with gut microbiota \[[@CR4]\]. The intestinal microbiota undergoes dynamic changes during childhood. Gut colonization in preterm infants occurs differently than in healthy term newborns \[[@CR5]\], and preterm infants frequently have delayed and aberrant acquisition of the "normal" digestive flora. Recent studies performed in preterm foetuses and infants demonstrated that amniotic fluid and meconium are not sterile, suggesting an intrauterine origin of gut microbiota \[[@CR6], [@CR7]\]; after birth, the preterm infant's immature intestine is exposed to an unique environment and to several iatrogenic manipulations, including the use of broad-spectrum antibiotics. The subsequent intestinal *dysbiosis* is recognized as a risk factor for NEC: actually, it has been shown that preterm infants with NEC have reduced bacterial gut diversity and different bacterial strains compared to healthy controls \[[@CR8]\]. In this perspective, provision of probiotics to preterm infants has the potential to "normalize" the abnormal colonization pattern, thus preventing the occurrence of the disease \[[@CR9]\].

The use of probiotics for the prevention of NEC in preterm infants has been extensively investigated in many randomized-controlled trials, whose results have been summarized in several systematic-reviews and meta-analyses \[[@CR10], [@CR11]\]. The authors of these meta-analyses, which show that probiotics reduce NEC and mortality in preterm infants, strongly encourage a change in practice, promoting a widespread use of probiotics in this population \[[@CR11]\], and also claim that withholding probiotics from high-risk neonates would be almost unethical \[[@CR10]\]. However, the position of the American Academy of Paediatrics is more cautious, highlighting the need for more studies to address unanswered questions on the amount and specificity of which probiotic or mixture of probiotics should be used \[[@CR12]\]. In addition, a recent systematic review, which analyzed the level of evidence of randomized-controlled trials on probiotics in preterm infants, concluded that there is still insufficient evidence to recommend routine probiotics use, but also that present data are encouraging and justify further research on specific probiotic products \[[@CR13]\].

Actually, the beneficial effects of probiotics appear to be strain-specific, and pooling data from studies using different strains can result in misleading conclusions \[[@CR14]\]. Furthermore, currently available studies often lack specificity in reporting correct identification of probiotic strain \[[@CR15]\], dosage regimen and duration, and gut colonization, which are all fundamental to assess the ability of a probiotic to confer a health benefit to the host \[[@CR16]\].

The aim of this meta-analysis is thus to evaluate in detail the effect of probiotics for the prevention of NEC in preterm infants, with a focus on specific strains, on microbiological strength of currently available studies, and on high-risk populations.

Methods {#Sec2}
=======

Literature search {#Sec3}
-----------------

The study protocol was designed jointly by the members of the Task Force on Probiotics of the Italian Society of Neonatology.

A systematic review of published studies reporting the use of probiotics for the prevention of NEC in preterm infants was performed, following PRISMA guidelines \[[@CR17]\].

Criteria for inclusion in the meta-analysis were the following: randomized and quasi-randomized controlled trials involving preterm infants (gestational age \<37 weeks) and reporting on NEC (any stage, according to modified Bell staging criteria \[[@CR18], [@CR19]\]); enteral administration of any probiotic starting within one month of age, compared to placebo or no treatment. Being the search strategy focused specifically on NEC, data on different outcomes, such as sepsis or mortality, which were reported in the studies retrieved by the literature search, were not evaluated by meta-analysis.

A search was conducted in PubMed (<http://www.ncbi.nlm.nih.gov/pubmed/>) for studies published before 4th February 2015, using the search string reported in Fig. [1](#Fig1){ref-type="fig"}. This string was built up combining all the terms related to NEC and probiotics, using PubMed MeSH terms and free-text words and their combinations through the most proper Boolean operators, in order to be as comprehensive as possible. Similar criteria were used for searching the Cochrane Library. The review was limited to studies written in English and involving human subjects.Fig. 1Flow chart showing the search strategy and search results. The relevant number of papers at each point is given

The search was conducted by AA and LC: relevant studies were identified from the abstract, and reference lists of papers retrieved were searched for additional studies. "Snowballing" technique was also used \[[@CR20]\].

Data extraction and meta-analysis {#Sec4}
---------------------------------

Study details, including study population, characteristics of the intervention, use of placebo, and outcome, were assessed independently by AA and LC, and checked by DG. Study quality was evaluated independently using the risk of bias tool as proposed by the Cochrane collaboration (Chapter 8 of the Cochrane Handbook of Systematic Reviews) \[[@CR21]\]. In addition, an assessment of the body of evidence using the GRADE working group approach was used in order to grade the quality of evidence. The evaluation was carried out following the Chapter 12 of the Cochrane Handbook \[[@CR21]\] and classifying the evidence as high, moderate, low and very low (as suggested by the GRADE Working Group) \[[@CR22]\].

The association between probiotic use and NEC was evaluated by meta-analyses, conducted by AA and DG, using the RevMan software (version 5.3.5; downloaded from the Cochrane website: <http://tech.cochrane.org/revman/download>). Risk ratio (RR) was calculated using the Mantel-Haenszel method, and reported with 95 % confidence interval (CI).

The following sub-meta-analyses were also performed, in order to evaluate the effect of probiotics:in specific subgroups of patients (very-low-birth-weight \[VLBW\] infants);in surgical NEC;according to NEC incidence in different populations: the incidence of NEC stage ≥2 in the control population was used as a reference, because only a minority of studies reported NEC incidence in the general population. Studies were arbitrarily divided into three groups defined as "low-risk" (NEC incidence \<5 %), "medium-risk" (incidence 5--10 %), and "high-risk" (incidence \>10 %);according to probiotic strain: studies were divided according to the specific probiotic strain used, and were considered as suitable for inclusion in the sub-meta-analyses when the same probiotic strain was used in at least two studies. Studies which used a probiotic mixture were considered together.

Microbiological quality of all the studies was evaluated by MLC and LM. Studies were defined as having severe, moderate or minor microbiological flaws according to the evaluation of proper strain identification and microbiological assessment. Specifically, the lack of proper strain identification was considered as a severe flaw; the lack of microbiological assessment regarding the probiotic persistence in stools was considered as a moderate flaw, whereas a low flaw was defined when the presence of the probiotic in stools was evaluated by indirect approaches such as the quantification of its species belonging.

A fixed-effect model was used for the analyses. Heterogeneity was measured using the I^2^ test. If significant heterogeneity was present (*p* \< 0.05 from the *χ*^2^ test), a random-effects model was used \[[@CR23]\]. The random-effects model was also used when heterogeneity was not significant but the number of studies was ≤ 5, because the test for heterogeneity is known to have low power when the number of studies is small \[[@CR24]\].

Forest plots were used to illustrate results from meta-analyses, and funnel plots to investigate bias.

The online version of GraphPad Quickcalcs software was used to calculate number needed to treat (NNT).

Results {#Sec5}
=======

Literature search {#Sec6}
-----------------

Three-hundred-sixty-eight papers were identified through the literature search (310 through PubMed and 58 through the Cochrane Library). Thirty-eight studies met the inclusion criteria: 22 were identified through the PubMed search \[[@CR25]--[@CR48]\] and 16 through the Cochrane Library search \[[@CR25], [@CR26], [@CR28]--[@CR32], [@CR34]--[@CR37], [@CR40]--[@CR43], [@CR45]\]. Ten additional papers were identified from the reference lists of included studies \[[@CR49]--[@CR58]\]. Of these 47 studies, 16 were excluded, as they were duplicates retrieved both by PubMed and Cochrane Library search. Six additional studies were excluded after examining the full-texts: one study reported maternal probiotic supplementation during pregnancy \[[@CR29]\], one cohort was reported twice \[[@CR31]\], one study included both term and preterm infants \[[@CR36]\], two studies did not report NEC data \[[@CR55], [@CR56]\], and in one study randomization was not declared \[[@CR54]\].

Twenty-six studies were suitable for inclusion in the meta-analysis \[[@CR10], [@CR25]--[@CR28], [@CR30], [@CR32]--[@CR35], [@CR37]--[@CR42], [@CR44], [@CR46], [@CR48]--[@CR53], [@CR58]\]. A description of included studies is provided in Table [1](#Tab1){ref-type="table"}; excluded studies are described in Table [2](#Tab2){ref-type="table"}.Table 1Studies included in the systematic review and meta-analysisAuthor, yearStudy detailsStudy populationInterventionType of milkPlacebo- Strain- Dose (D)- Start of treatment (S)- End of treatment (E)Al-Hosni, 2012 \[[@CR33]\]PPreterm infants with BW 501--1000 g, appropriate for gestational age, and ≤ 14 days of age at time of feeding initiation*Lactobacillus rhamnosus GG LGG*Non specifiedExtra milkDB*Bifidobacterium infantis*RD: 0.5 × 10^9^ CFU each probiotic, ODCS: first enteral feedingMultic.E: discharge or until 34 w postmenstrual ageBin-Nun, 2005 \[[@CR40]\]PPreterm infants with BW \< 1500 g, who began enteral feeding on a weekday*Bifidobacterium infantis*OMM, PFMHM or FMB*Streptococcus thermophilus*R*Bifidobacterium bifidus*CD: 0.35 × 10^9^ CFU each probiotic, ODS: start of enteral feedingE: 36 w postconceptual ageBraga, 2011 \[[@CR35]\]PInborn infants with BW 750--1499 g*Lactobacillus casei*HMExtra HMDB*Bifidobacterium breve*RD: 3.5 × 10^7^ CFU to 3.5 × 10^9^ CFU ODCS: day 2E: day 30, NEC diagnosis, discharge, death, whichever occurred firstCostalos, 2003 \[[@CR49]\]PGA 28--32 w*Saccharomyces boulardii*PFMMDXRNo major GI problemD: 1 × 10^9^ CFU BDCNot receiving antibioticsS: non-specifiedNot receiving breast milkMedian duration of probiotic supplementation: 30 daysDani, 2002 \[[@CR42]\]PInfants with GA \< 33 w or BW \< 1500 g*Lactobacillus rhamnosus GG*OMM, DM or FMMDXDBD: 6 × 10^9^ CFU ODRS: first feedCE: dischargeMultic.Demirel, 2013 \[[@CR28]\]PPreterm infants with GA ≤ 32 w and BW ≤ 1500 g, who survived to feed enterally*Saccharomyces boulardii*HM, FMNoneBD: 5 × 10^9^ CFU ODRS: first feedCE: dischargeDilli, 2015 \[[@CR44]\]PPreterm infants with GA \<32 weeks and BW \<1500 g, born at or transferred to the NICU within the first week of life and fed enterally before inclusion*Bifidobacterium*HM, FMMDX powderDB*Lactis*RD: 5 × 10^9^ CFUCS: beyond d7 after birthMultic.E: death or discharge (max 8 weeks)Fernández-Carrocera, 2013 \[[@CR32]\]PPreterm infants with BW \< 1500 g*Lactobacillus acidophilus* 1 CFU/gOMM, PFMNoneDBInfants with NEC IA and IB were excluded*Lactobacillus rhamnosus* 4.4 × 10^8^ CFU/gR*Lactobacillus casei* 1 × 10^9^ CFU/gC*Lactobacillus plantarum* 1.76 × 10^8^ CFU/g*Bifidobacterium infantis* 2.76 × 10^7^ CFU/g*Streptococcus thermophilus* 6.6 × 10^5^ CFU/gTotal D: 1 g powder ODS: start of enteral feedingE: non-specifiedJacobs, 2013 \[[@CR26]\]PPreterm infants with GA \<32 w and BW \< 1500 g*Bifidobacterium infantis BB-02* 300 CFU × 10^6^HM, FMMDX powderDB*Streptococcus thermophilus Th-4* 350 CFU × 10^6^R*Bifidobacterium lactis BB-12* 350 CFU × 10^6^CTotal D: 1 × 10^9^ CFU × 1.5 g maltodextrin powder ODMultic.S: enteral feed ≥ 1 ml every 4 hE: discharge or term corrected ageKitajima, 1997 \[[@CR52]\]PPreterm infants with BW \< 1500 g*Bifidobacterium breve YIT4010*OMM, FM after full enteral feeding had been reachedDistilled waterRD: 0.5 × 10^9^ CFU ODCS: within 24 h of lifeDuration of probiotic supplementation: 28 daysLin, 2005PInfants with BW \< 1500 g, who started to feed enterally and survived beyond day 7*Lactobacillus acidophilus*OMM, DMNoneM*Bifidobacterium infantis*RD: ≥ 10^6^ CFU each probiotic (=125 mg/kg), BDCS: start of enteral feedingE: dischargeLin, 2008PPreterm infants with GA \< 34 w and BW ≤ 1500 g, who survived to feed enterally*Lactobacillus acidophilus NCDO 1746*HM, FMNoneB*Bifidobacterium bifidum NCDO 1453*RD: 1 × 10^9^ CFU each probiotic (=125 mg/kg) BDCS: day 2 of ageMultic.Duration: 6 weeksManzoni, 2006 \[[@CR37]\]PInfants with BW \< 1500 g, ≥ 3 days of life, who started enteral feeding with HM*Lactobacillus rhamnosus LGG*OMM, DMNoneDBD: 6 × 10^9^ CFU/dayRS: day 3 of lifeCE: end of the 6th week or dischargeMihatsch, 2010 \[[@CR43]\]PPreterm infants with GA \< 30 w and BW ≤ 1500 g*Bifidobacterium lactis BB12*HM, PFMIndistinguishable powderRD: 2 × 10^9^ CFU/kg 6 times a dayCS: start of enteral feedingE: non-specifiedMohan, 2006 \[[@CR53]\]PPreterm infants (GA \< 37 w)*Bifidobacterium lactis BB12*FMNot statedDBD: 1.6 × 10^9^ CFU on day 1 to 3, and 4.8 × 10^9^ CFU from day 4 onwardsRS: first day of lifeCDuration: 21 daysOncel, 2013 \[[@CR25]\]PPreterm infants with GA ≤ 32 w and BW ≤ 1500 g, who survived to feed enterally*Lactobacillus reuteri DSM 17938*HM, FMOil baseDBD: 1 × 10^8^ CFU ODRS: first feedCE: death or dischargePatole, 2014 \[[@CR45]\]PPreterm infants with GA \< 33 w and BW \< 1500 g*Bifidobacterium breve* M16-VHM, FMDextrinDBD: 3 × 10^9^ CFU OD (1.5 × 109 CFU OD for newborns ≤ 27 w until they reached 50 ml/kg/day enteral feeds)RS: start of enteral feedCE: corrected age of 37 wRojas, 2012 \[[@CR30]\]PPreterm infants with BW ≤ 2000 g, hemodynamically stable, ≤ 48 h of age (regardless start of enteral feeding)*Lactobacillus reuteri DSM 17938*HM, FMOil baseDBD: 1 × 10^8^ CFU ODRS: age ≤ 48 hCE: death or dischargeMultic.Rougé, 2009 \[[@CR50]\]PPreterm infants with GA \< 32 w and BW \< 1500 g, ≤ 2 w of age, without any disease other than those linked to prematurity, who started enteral feeding before inclusion*Bifidobacterium longum BB536*OMM, DM or PFMMDXDB*Lactobacillus rhamnosus GG BB536-LGG*RTotal D: 1 × 10^8^ CFU/dayCS: start of enteral feedingBic.E: dischargeRoy, 2014 \[[@CR58]\]PPreterm infants (GA \< 37w) and BW \< 2500 g, with stable enteral feeding within 72 h of birth*Lactobacillus acidophilus* 1.25 × 10^9^ CFU × 1 gHMSterile waterDB*B. longum* 0.125 × 10^9^ CFU × 1 gR*B. bifidum* 0.125 × 10^9^ CFU × 1 gC*B. lactis* 1 × 10^9^ CFU × 1 gD: half a 1 g sachetS: from 72 h of lifeE: after 6 w or at dischargeSaengtawesin, 2014 \[[@CR48]\]PPreterm infants with GA ≤ 34 w and BW ≤ 1500 g*Lactobacillus acidophilus* 1 × 10^9^ CFUHM, PFMNoneR*Bifidobacterium*C*bifidum* 1 × 10^9^ CFUD: 125 mg/kg BDS: start of feedingE: 6 w of age or discharge.Samanta, 2009PPreterm infants with GA \< 32 w and BW \< 1500 g, who started enteral feeding and survived beyond 48 h of age*Bifidobacterium infantis*HMNoneDB*Bifidobacterium bifidum*R*Bifidobacterium longum*C*Lactobacillus acidophilus*D: 2.5 × 10^9^ CFU each probiotic, BDS: start of enteral feedingE: dischargeSari, 2011 \[[@CR34]\]PPreterm infants with GA \< 32 w or BW \< 1500 g, who survived to feed enterally*Lactobacillus sporogenes*HM, FMNoneBD: 0.35 × 10^9^ CFU ODRS: first feedCE: dischargeSerce, 2013 \[[@CR27]\]PPreterm infants with GA ≤ 32 w and BW ≤ 1500 g, who survived to feed enterally*Saccharomyces boulardii*HM, FMDistilled waterMD: 0.5 × 10^9^ CFU/kg BDRS: non-specifiedCE: non-specifiedStratiki, 2007 \[[@CR39]\]PPreterm infants with GA 27--32 w, formula-fed, without major congenital anomalies*Bifidobacterium lactis*FMNoneBD: 2 × 10^7^ CFU/g of milk powderRS: start of enteral feedingCE: non-specifiedTotsu, 2014 \[[@CR46]\]PInfants with BW \< 1500 g*Bifidobacterium bifidum*HM, FMDextrinDBD: 2.5 × 10^9^ CFU, divided in two dosesCLRS: within 48 h after birthCE: body weight 2000 gMultic.*P* prospective, *DB* double-blinded, *R* randomized, *C* controlled, *Multic* multicentric, *B* blinded, *M* masked, *Bic* bicentric, *BW* birth weight, *GA* gestational age, *NEC* necrotizing enterocolitis, *HM* human milk, *CFU* colony forming unit, *OD* once daily, *BD* twice daily, *OMM* own mother's milk, *PFM* preterm formula, *DM* donor milk, *FM* formula, *MDX* maltodextrinTable 2Studies excluded from the systematic review and meta-analysisAuthor, yearStudy summaryReason for exclusionAwad, 2010Living vs. killed *Lactobacillus acidophilus* vs. placebo given to neonates admitted to the study NICUTerm and preterm infants includedBenor, 2014*Lactobacillus acidophilus* and *Bifidobacteria lactis* vs. placebo given to mothers of VLBW infantsMaternal probiotic supplementationLi, 2004*Bifidobacterium breve* given to LBW infantsRandomization not declaredMillar, 1993*Lactobacillus GG* given to preterm infants with GA \< 33 wNo NEC dataReuman, 1986Formula containing lactobacilli vs. placebo given to preterm infantsNo NEC dataSari, 2012*Lactobacillus sporogenes* given to preterm infants with GA \< 32 w or BW \< 1500 g, who survived to feed enterallyDuplicate population (Sari, 2011 \[[@CR34]\])*NICU* neonatal intensive care unit, *VLBW* very low birth weight, *LBW* low birth weight, *GA* gestational age, *NEC* necrotizing enterocolitis, *BW* birth weight

All the studies reported NEC data in a form suitable for meta-analysis, except one \[[@CR53]\], for which data included in a previous Cochrane review were used \[[@CR59]\]. For each study, NEC rate in the probiotic and in the placebo/control group is reported in Table [3](#Tab3){ref-type="table"}. For the purpose of the meta-analysis, data on NEC stage ≥2 were used.Table 3Incidence of necrotizing enterocolitis in infants treated with probiotics and in controlsAuthor, yearPrevious NEC rateNumber of subjectsNEC in probiotic groupNEC in control groupAl-Hosni, 2012 \[[@CR33]\]Not stated50 probiotic3/50 any stage4/51 any stage51 control1/50 stage 12/51 stage 10/50 stage 20/51 stage 22/50 stage 32/51 stage 3Bin-Nun, 2005 \[[@CR40]\]15 %72 probiotic3/72 any stage12/73 any stage73 control1/72 stage ≥210/73 stage ≥21/72 stage 27/73 stage 20/72 stage 33/73 stage 3Braga, 2011 \[[@CR35]\]10 %119 probiotic0/119 stage ≥24/112 stage ≥2112 placeboCostalos, 2003 \[[@CR49]\]Not stated51 probiotic5/51 any stage6/36 any stage36 placeboDani, 2002 \[[@CR42]\]Not stated295 probiotic4/295 stage ≥28/290 stage ≥2290 placeboDemirel, 2013 \[[@CR28]\]32 %135 probiotic6/135 stage ≥27/136 stage ≥2136 controlDilli, 2015 \[[@CR44]\]Not stated100 probiotic2/100 stage ≥218/100 stage ≥2100 placeboFernández-Carrocera, 2013 \[[@CR32]\]20 %75 probiotic6/75 stage ≥212/75 stage ≥275 placeboJacobs, 2013 \[[@CR26]\]Not stated548 probiotic11/548 stage ≥224/551 stage ≥2551 placeboKitajima, 1997 \[[@CR52]\]Not stated45 probiotic0/45 any stage0/46 any stage46 placeboLin, 2005 \[[@CR41]\]Approx. 23 % (NEC or death)180 probiotic2/180 stage ≥210/187 stage ≥2187 control2/180 stage 24/187 stage 20/180 stage 36/187 stage 3Lin, 2008 \[[@CR37]\]Approx.217 placebo4/217 any stage14/217 any stage217 control2/217 stage 29/217 stage 22/217 stage 35/217 stage 3Manzoni, 2006 \[[@CR37]\]Not stated39 probiotic1/39 any stage3/41 any stage41 control1/39 stage 22/41 stage 20/39 stage 31/41 stage 3Mihatsch, 2010 \[[@CR43]\]Not stated84 probiotic2/84 stage ≥24/82 stage ≥282 placeboMohan, 2006 \[[@CR53]\]Not stated21 probiotic2/37 stage ≥21/32 stage ≥217 placeboUnpublished data, taken from Alfaleh 2011 \[[@CR58]\]Unpublished data, taken from Alfaleh 2011 \[[@CR58]\]Oncel, 2013 \[[@CR25]\]15 %200 probiotic8/200 stage ≥210/200 stage ≥2200 placeboPatole, 2014 \[[@CR45]\]Not stated74 probiotic0/74 stage ≥21/66 stage ≥266 placeboRojas, 2012 \[[@CR30]\]Not stated372 probioticNEC stage ≥2NEC stage ≥2378 placebo≤1500 g≤1500 g6/176 probiotic10/184 placebo\>1500 g\>1500 g3/196 probiotic5/194 placeboRougé, 2009 \[[@CR50]\]Not stated45 probiotic2/45 any stage1/49 any stage49 placeboRoy, 2014 \[[@CR58]\]Not stated56 probiotic2/56 any stage2/56 any stage56 placeboSaengtawesin, 2014 \[[@CR48]\]Not stated31 probiotic1/31 stage ≥21/29 stage ≥229 placeboSamanta, 2009Not stated91 probiotic5/91 stage ≥215/95 stage ≥295 controlSari, 2011 \[[@CR34]\]Approx. 32 % (death or NEC)110 probiotic6/110 stage ≥210/111 stage ≥2111 control4/110 stage 27/111 stage 22/110 stage 33/111 stage 3Serce, 2013 \[[@CR27]\]17 %104 probiotic7/104 stage ≥27/104 stage ≥2104 placeboStratiki, 2007 \[[@CR39]\]Not stated41 probiotic0/41 stage ≥23/34 stage ≥234 controlTotsu, 2014 \[[@CR46]\]Not stated153 probiotic0/153 stage ≥10/130 stage ≥1130 control*NEC* necrotizing enterocolitis

Probiotics and NEC stage ≥2 {#Sec7}
---------------------------

Data from 6605 infants (3324 in the probiotic group and 3281 in the control group) were analyzed. Fewer infants in the probiotic group developed NEC stage ≥2 compared to infants in the control group (88 \[2.65 %\] vs. 188 \[5.73 %\], respectively). The RR was significantly lower in infants treated with probiotics (0.47 \[95 % CI 0.36--0.60\], *p* \< 0.00001; fixed-effect analysis). NNT was 33 (95 % CI 24.7--47.2), which means that 33 infants needed to be treated with probiotics in order to prevent one more case of NEC stage ≥2. Heterogeneity among trials was absent (I^2^ = 0 %, *p* = 0.63; Fig. [2a](#Fig2){ref-type="fig"}). The funnel plot did not show any clear asymmetry (Fig. [2b](#Fig2){ref-type="fig"}).Fig. 2Forest plot (2**a**) and funnel plot (2**b**) of the included studies. The forest plot shows the association between the use of probiotics and necrotizing enterocolitis in the overall population of preterm infants. The funnel plot does not show any clear visual asymmetry. M-H: Mantel-Haenszel method

VLBW infants {#Sec8}
------------

Twenty-two studies \[[@CR25]--[@CR28], [@CR30], [@CR32]--[@CR35], [@CR37], [@CR38], [@CR40]--[@CR42], [@CR44]--[@CR46], [@CR48], [@CR50]--[@CR52]\] reported data from 5912 VLBW infants, 2959 in the probiotic and 2953 in the control group. NEC stage ≥2 occurred less frequently in the probiotic group than in controls (82 \[2.77 %\] infants vs. 174 \[5.89 %\], respectively), with a RR of 0.48 (\[95 % CI 0.37--0.62\], *p* \< 0.00001; fixed-effect analysis; I^2^ = 0 %, *p* = 0.56). NNT was 33 (95 % CI 24.1--47.9).

Surgical NEC {#Sec9}
------------

Only 6 studies \[[@CR33], [@CR34], [@CR37], [@CR40], [@CR41], [@CR51]\] reported separate data for surgical NEC (NEC stage 3), which occurred in 6/668 (0.90 %) infants in the probiotic group and in 20/680 (2.94 %) infants in the control group. The RR for NEC stage 3 was significantly lower in the probiotic group (0.35 \[95 % CI 0.16--0.81\], *p* = 0.01; fixed-effect analysis; I^2^ = 0 %, *p* = 0.69). NNT was 49 (95 % CI 28.6--170.8).

NEC incidence {#Sec10}
-------------

NEC incidence in controls was \<5 % in 13 studies (Fig. [3a](#Fig3){ref-type="fig"}) \[[@CR26], [@CR30], [@CR33], [@CR35], [@CR42], [@CR43], [@CR45], [@CR46], [@CR48], [@CR50], [@CR52], [@CR53], [@CR58]\], between 5 and 10 % in 8 studies (Fig. [3b](#Fig3){ref-type="fig"}) \[[@CR25], [@CR27], [@CR28], [@CR34], [@CR37], [@CR39], [@CR41], [@CR51]\], and \>10 % in 5 studies (Fig. [3c](#Fig3){ref-type="fig"}) \[[@CR32], [@CR38], [@CR40], [@CR44], [@CR49]\].Fig. 3Forest plot showing the association between the use of probiotics and necrotizing enterocolitis (NEC), according to NEC incidence: (3**a**). NEC incidence \< 5 %; (3**b**). NEC incidence 5--10 %; (3**c**). NEC incidence \>10 %. M-H: Mantel-Haenszel method

The RR for NEC stage ≥2 was significantly lower in the probiotic group compared to the control group in all the three populations (RR 0.52 \[95 % CI 0.35--0.78\], *p* = 0.001; RR 0.54 \[95 % CI 0.36--0.80\], *p* = 0.002; RR 0.33 \[95 % CI 0.17--0.62\], *p* = 0.0006, respectively). Heterogeneity was non-significant in all the three sub-analyses.

Probiotic strain {#Sec11}
----------------

*Lactobacillus GG* was used in 2 studies \[[@CR42], [@CR51]\] and *Lactobacillus reuteri* in 2 other studies \[[@CR25], [@CR30]\]: the effect of these probiotics in reducing NEC was not significant, either for *Lactobacillus GG* and *Lactobacillus reuteri* (RR 0.50 \[95 % CI 0.17--1.44\], *p* = 0.20 \[Fig. [4a](#Fig4){ref-type="fig"}\], and RR 0.69 \[95 % CI 0.38--1.26\], *p* = 0.23 \[Fig. [4b](#Fig4){ref-type="fig"}\]). One study used *Lactobacillus sporogenes* \[[@CR34]\].Fig. 4Forest plot showing the association between probiotics and necrotizing enterocolitis in the studies which used a single-strain product containing *Lactobacilli* ((4**a**). *L. reuteri*; (4**b**). *L. GG*; (4**c**). pooled analysis of all the studies using *Lactobacilli*). M-H: Mantel-Haenszel method

The results of all the studies including *Lactobacilli* were pooled, except for the study by Sari et al. \[[@CR34]\]: *Lactobacillus sporogenes* is a species which has not an international recognition, shows characteristics of both *genera Lactobacillus* and *Bacillus*, and its strains should be better classified as *Bacillus coagulans* \[[@CR60]\]. Thus, when the results of studies using *Lactobacillus GG* and *reuteri* were pooled, no significant reduction in the RR for NEC in the probiotic group was observed (0.62 \[95 % CI 0.37--1.05\], *p* = 0.07, Fig. [4c](#Fig4){ref-type="fig"}).

Four studies used *Bifidobacterium lactis* \[[@CR39], [@CR43], [@CR44], [@CR53]\], 2 studies *Bifidobacterium breve* \[[@CR45], [@CR52]\] and 1 study *Bifidobacterium bifidum* \[[@CR46]\]. The use of *Bifidobacterium lactis* resulted in a significant reduction in the RR for NEC (0.23 \[95 % CI 0.10--0.55\], *p* = 0.0008, Fig. [5a](#Fig5){ref-type="fig"}). No effect of *Bifidobacterium breve* in reducing NEC was documented (RR 0.30 \[95 % CI 0.01--7.19\], *p* = 0.46, Fig. [5b](#Fig5){ref-type="fig"}); the only study reporting the use of *Bifidobacterium bifidum* did not report any case on NEC. When the results of studies using *Bifidobacteria* were pooled, a significant reduction in the RR for NEC in the probiotic group was observed (0.24 \[95 % CI 0.10--0.54\], *p* = 0.0006, Fig. [5c](#Fig5){ref-type="fig"}).Fig. 5Forest plot showing the association between probiotics and necrotizing enterocolitis in the studies which used a single-strain product containing *Bifidobacteria* ((5**a**). *B. lactis*; (4**b**). *B. breve*; (4**c**). pooled analysis of all the studies using *Bifidobacteria*). M-H: Mantel-Haenszel method

*Saccharomyces boulardii* was used in 3 studies \[[@CR27], [@CR28], [@CR49]\]: no significant effect of this probiotic was documented (RR 0.81 \[95 % CI 0.44--1.49\], *p* = 0.50; random effects analysis).

The pooled analysis of the 11 studies \[[@CR26], [@CR32], [@CR33], [@CR35], [@CR37], [@CR38], [@CR40], [@CR41], [@CR48], [@CR50], [@CR58]\] in which a probiotic mixture was used showed an overall and significant benefit of these products in reducing NEC (RR 0.39 \[95 % CI 0.27--0.56\], *p* \< 0.00001, Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Forest plot showing the association between probiotics and necrotizing enterocolitis in the studies which used a probiotic mix. M-H: Mantel-Haenszel method

Study quality {#Sec12}
-------------

Evaluation of the quality of the studies included in the meta-analysis according to the risk of bias tool as proposed by the Cochrane Collaboration is showed in Table [4](#Tab4){ref-type="table"}, which also shows the level of evidence evaluated following the recommendations of the GRADE Working Group.Table 4Evaluation of the quality of the studies included in the meta-analysis according to the risk of bias tool as proposed by the Cochrane collaboration and evaluation of the level of evidence according to the GRADE approachStudyRandom sequence generationAllocation concealmentBlindingIncomplete outcome dataSelective outome reportingOther sources of biasLevels of quality of evidence in the grade approachAl-Hosni, 2012 \[[@CR33]\]UNCLEARUNCLEARLOWUNCLEARUNCLEARUNCLEARLOWBin-Nun, 2005 \[[@CR40]\]UNCLEARUNCLEARHIGHUNCLEARUNCLEARUNCLEARVERYLOWBraga, 2011 \[[@CR35]\]LOWLOWLOWLOWUNCLEARLOWHIGHCostalos, 2003 \[[@CR49]\]LOWLOWLOWLOWUNCLEARLOWHIGHDani, 2002 \[[@CR42]\]UNCLEARLOWLOWLOWUNCLEARUNCLEARMODERATEDemirel, 2013 \[[@CR28]\]LOWLOWLOWUNCLEARUNCLEARUNCLEARMODERATEDilli, 2015 \[[@CR44]\]LOWLOWLOWUNCLEARUNCLEARUNCLEARMODERATEFernández-Carrocera, 2013 \[[@CR32]\]LOWLOWLOWLOWUNCLEARLOWHIGHJacobs, 2013 \[[@CR26]\]LOWUNCLEARLOWUNCLEARUNCLEARUNCLEARLOWKitajima, 1997 \[[@CR52]\]LOWUNCLEARLOWUNCLEARUNCLEARLOWMODERATELin, 2005 \[[@CR41]\]LOWLOWLOWLOWUNCLEARLOWHIGHLin, 2008 \[[@CR37]\]LOWLOWLOWLOWUNCLEARLOWHIGHManzoni, 2006 \[[@CR37]\]LOWLOWLOWUNCLEARUNCLEARLOWMODERATEMihatsch, 2010 \[[@CR43]\]LOWUNCLEARLOWLOWUNCLEARLOWMODERATEMohan, 2006 \[[@CR53]\]UNCLEARLOWLOWUNCLEARUNCLEARUNCLEARLOWOncel, 2013 \[[@CR25]\]LOWUNCLEARLOWLOWUNCLEARUNCLEARMODERATEPatole, 2014 \[[@CR45]\]LOWLOWLOWLOWUNCLEARLOWHIGHRojas, 2012 \[[@CR30]\]LOWLOWLOWLOWUNCLEARLOWHIGHRougé, 2009 \[[@CR50]\]LOWUNCLEARUNCLEARUNCLEARUNCLEARHIGHLOWRoy, 2014 \[[@CR58]\]LOWUNCLEARLOWLOWUNCLEARUNCLEARMODERATESaengtawesin, 2014 \[[@CR48]\]HIGHHIGHHIGHUNCLEARUNCLEARUNCLEARLOWSamanta, 2009LOWLOWLOWUNCLEARUNCLEARUNCLEARMODERATESari, 2011 \[[@CR34]\]LOWLOWLOWUNCLEARUNCLEARUNCLEARMODERATESerce, 2013 \[[@CR27]\]LOWLOWLOWUNCLEARUNCLEARLOWMODERATEStratiki, 2007 \[[@CR39]\]UNCLEARUNCLEARLOWUNCLEARUNCLEARLOWLOWTotsu, 2014 \[[@CR46]\]LOWLOWLOWLOWUNCLEARUNCLEARMODERATE

Microbiological quality {#Sec13}
-----------------------

Microbiological quality of included studies is described in Table [5](#Tab5){ref-type="table"}. Eight studies were evaluated as having severe microbiological flaws \[[@CR27], [@CR32], [@CR34], [@CR35], [@CR38], [@CR40], [@CR41], [@CR49]\], meaning that they did not report a proper probiotic strain identification. Thirteen studies \[[@CR25], [@CR26], [@CR28], [@CR30], [@CR33], [@CR37], [@CR42]--[@CR44], [@CR46], [@CR48], [@CR51], [@CR58]\] were evaluated as having moderate microbiological flaws, because none of them evaluated the probiotic persistence in stools. There were only five studies \[[@CR39], [@CR45], [@CR50], [@CR52], [@CR53]\] with minor microbiological flaws.Table 5Evaluation of the included studies according to their microbiological qualityAuthor, yearProbiotic strainStrain identificationMicrobiological assessmentMicrobiological flawAl-Hosni, 2012 \[[@CR33]\]Lactobacillus rhamnosus LGGLGG identified at the strain levelNo assessmentModerateBifidobacterium infantis*B. infantis* identified via the web site of the producer: Bifantis (*Bifidobacterium infantis* 35624)Bin-Nun, 2005 \[[@CR40]\]Bifidobacterium infantisStrains not identified at the strain levelNo assessmentSevereStreptococcus thermophilusBifidobacterium bifidusBraga, 2011 \[[@CR35]\]Lactobacillus caseiStrains non identified clearlyNo assessmentSevereBifidobacterium breveCostalos, 2003 \[[@CR49]\]Saccharomyces boulardiiStrain not identified at the strain level*S. boulardii* not characterized in stools.SevereGut flora assessed by plate countDani, 2002 \[[@CR42]\]Lactobacillus rhamnosus GGStrain identifiedNo assessmentModerateDemirel, 2013 \[[@CR28]\]Saccharomyces boulardiiStrain identifiedNo assessmentModerateDilli, 2015 \[[@CR44]\]*B. lactis*Strain non identified at the strain level but probably Bb12No assessmentModerateFernández-Carrocera, 2013 \[[@CR32]\]Lactobacillus acidophilusStrains not identified at the strain levelNo assessmentSevereLactobacillus rhamnosusLactobacillus caseiLactobacillus plantarumBifidobacterium infantisStreptococcus thermophilusJacobs, 2013 \[[@CR26]\]Bifidobacterium infantisStrains identified at the strain levelNo assessmentModerateStreptococcus thermophilus Bifidobacterium lactisKitajima, 1997 \[[@CR52]\]Bifidobacterium breveStrain identifiedAssessment by a strain-specific monoclonal antibody conjugated with colloidal gold particleMinorLin, 2005 \[[@CR41]\]Lactobacillus acidophilusStrains not identified at the strain levelNo assessmentSevereBifidobacterium infantisLin, 2008 \[[@CR37]\]Lactobacillus acidophilusStrain identifiedNo assessmentModerateBifidobacterium bifidumManzoni, 2006 \[[@CR51]\]Lactobacillus rhamnosus LGGStrain identifiedNo assessmentModerateMihatsch, 2010 \[[@CR43]\]Bifidobacterium lactisStrain identifiedNo assessmentModerateMohan, 2006 \[[@CR53]\]Bifidobacterium lactisStrain identifiedSpecies-specific (not strain-specific) assessmentMinorOncel, 2013 \[[@CR25]\]Lactobacillus reuteriStrain identifiedNo assessmentModeratePatole, 2014 \[[@CR45]\]Bifidobacterium breveStrain identifiedMicrobiological assessment by PCRMinorRojas, 2012 \[[@CR30]\]Lactobacillus reuteriStrain identifiedNo assessmentModerateRougé, 2009 \[[@CR50]\]Bifidobacterium longumStrain identifiedMicrobiological assessment by PCRMinorLactobacillus rhamnosus GGRoy, 2014 \[[@CR58]\]Lactobacillus acidophilus, B. longum, B. bifidum, and B. lactisStrains not identified at the strain level/identification of the commercial productNo assessmentModerateSaengtawesin, 2014 \[[@CR48]\]Lactobacillus acidophilus and Bifidobacterium bifidumStrains not identified at the strain level/identification of the commercial productNo assessmentModerateSamanta, 2009Bifidobacterium infantisStrains not identified at the strain levelNo assessmentSevereBifidobacterium bifidumBifidobacterium longumLactobacillus acidophilusSari, 2011 \[[@CR34]\]Lactobacillus sporogenesStrains not identified at the strain levelNo assessmentSevereSerce, 2013 \[[@CR27]\]Saccharomyces boulardiiStrains not identified at the strain levelNo assessmentSevereStratiki, 2007 \[[@CR39]\]Bifidobacterium lactisStrain identifiedAssessment by plate count, no strain-specific assessmentMinorTotsu, 2014 \[[@CR46]\]Bifidobacterium bifidumStrain identifiedNo assessmentModerate

Discussion {#Sec14}
==========

The results of this systematic review and meta-analysis show an overall benefit of probiotic supplementation for the prevention of NEC in preterm infants. These results are strengthened by the absence of significant statistical heterogeneity among studies and by the low-risk of publication bias documented by the funnel plot.

However, despite the overall benefit, it is remarkable that the 26 studies included in the meta-analysis were extremely heterogeneous in terms of probiotic strain, dosage, duration of intervention, and target population. Furthermore, only few studies documented an effective colonization of the infants' gut with the probiotic strain. Thus, the proposal made by the authors of the recent Cochrane review of a "change in practice" in the use of probiotics in preterm infants \[[@CR11]\] might require further investigation.

Currently available literature does not provide any definite conclusion on which probiotic strain should be used, and which group of preterm infants would benefit most from a probiotic intervention. It is important to note that the effect of a live-microorganism used as a probiotic is strictly strain-specific \[[@CR61]\]. In this paper we aimed to perform strain-specific sub-meta-analyses but our efforts were weakened by the fact that in very few studies the same probiotic strain was used. For this reason, we were unable to draw definite conclusions on which single-strain of probiotics would be more effective in reducing NEC. When studies using single strains were pooled according to the probiotic *genus*, no significant effect was documented for *Lactobacilli* and *Saccharomyces*. This is partially in contrast with the recent Cochrane review on probiotics and NEC \[[@CR11]\], which showed a beneficial effect of *Lactobacilli*: this discrepancy appears to be due mainly to differences in the studies included in the two sub-meta-analyses. Actually, the present meta-analysis included the study by Oncel et al. \[[@CR25]\], which was on-going when the Cochrane review was published, but excluded the study by Manzoni et al. \[[@CR57]\], where probiotics were used in addition to lactoferrin, and the study by Sari et al. \[[@CR34]\], which used a probiotic product which is not properly a *Lactobacillus* \[[@CR60]\].

The analysis of studies using *Bifidobacteria* showed a significant effect of *Bifidobacterium breve* in reducing NEC. This is also in contrast with the results of the Cochrane review; however, the discrepancy is explained by the inclusion in the present meta-analysis of the recent study by Dilli et al. \[[@CR44]\], which appears to drive the beneficial effect documented for *Bifidobacteria*. Similarly to the Cochrane review \[[@CR11]\], the analysis of studies in which more than one strain was used documented a strong and significant effect of these products in the prevention of NEC. No definite conclusion can be drawn from these results, even if it could be suggested that further research should be focused on mixed rather than on single-strain products; a potential rationale for this approach could be that a mix of strains might be more effective in providing an ecological barrier than a single strain.

The evidence that probiotics are effective in reducing NEC in VLBW infants does not necessarily apply also to extremely LBW infants (ELBWs), who are the highest-risk population. Only three studies \[[@CR26], [@CR33], [@CR58]\] reported the rate of NEC in ELBWs: in two of these studies \[[@CR33], [@CR58]\], the same number of ELBWs in the probiotic and control group developed NEC \[[@CR33]\], while in the ProPrems trial NEC incidence was slightly lower in the probiotic group \[[@CR26]\]. Given the relatively small number of ELBWs and the inconclusive results, no specific recommendation can be drawn from the analysis of these two studies. Similarly, no study reported separate data for intrauterine-growth-restricted (IUGR) infants, and thus no recommendation can be made either for this high-risk population.

In the analysis of trials evaluating a specific intervention, it is pivotal to understand whether the results of these trials are generalizable or applicable only in specific clinical settings. According to our data, the common belief that probiotics are more effective in populations with a high rate of NEC \[[@CR62]\] can be called into question: actually, when studies were divided according to NEC incidence in the control population, NEC reduction was striking and significant also when NEC rate in controls was extremely low. NEC rate in controls can be considered as a proxy for the quality of neonatal care: in this perspective, it is interesting to note that, in contrast with previous data, probiotics appear to confer a preventive benefit also in high quality-of-care settings. NEC rate in control populations was used for the analysis, rather than the baseline NEC rate stated by the authors and used in several studies for sample size calculation: this approach was considered more appropriate, because baseline NEC rate was not provided in many studies and, when provided, there was often a discrepancy with NEC rate detected in controls.

The analysis of included studies according to their microbiological quality points out that clinical studies aiming at evaluate the preventive effect of probiotics on NEC often lack an adequate microbiological assessment and this represents a major limitation of these studies. Actually, it is well known that the correct identification of a probiotic at species level corresponds to evaluate its safety, whereas the identification at strain level is extremely relevant as probiotic beneficial properties are strain-specific. Furthermore, the evaluation of probiotic colonisation, even if temporary, is important to correlate the probiotic presence to the beneficial effects.

The development of gut microbiota in preterm infants is known to be influenced by several factors, including gestational age, mode of delivery, diet, and antibiotic exposure \[[@CR63]\]. All these factors are likely to be significant confounders in the relationship between probiotics and NEC: actually, it is well documented that infants fed maternal or donor breast milk have a lower risk of NEC compared to formula-fed infants \[[@CR64]\], and that caesarean delivery is associated with a disruption in gut microbiota \[[@CR65]\]. Quite surprisingly, however, in published studies data are not analyzed taking these confounders into account \[[@CR66]\]. Given the definite protective role of human milk feeding and the symbiotic properties of human milk, it would be fundamental to understand whether the use of probiotics should be encouraged also in human-milk fed infants, or if this intervention should be directed towards exclusively formula-fed infants.

The studies included in the meta-analysis did not report any short-term adverse effect of probiotic supplementation (i.e., bloodstream infection with the probiotic strain). Growing evidence suggests the influence of gut microbiota on long-term health and disease, including both type 1 and type 2 diabetes mellitus, atherosclerosis, asthma, colon cancer, and inflammatory bowel disease \[[@CR67]\]. However, at present little is known on the long-term outcome possibly related to the alteration of gut flora in preterm infants, which is the result of the supplementation with exogenous strains.

The choice to investigate a single outcome might be viewed as a limitation of the study: however, this choice was deliberate, as the literature search strategy was focused exclusively on NEC. Any speculation on different outcomes such as sepsis or mortality would have been inevitably misleading, because it would have been impossible to be sure to have identified all the studies reporting on those outcomes.

Conclusions {#Sec15}
===========

Meta-analyses give a valuable contribution in guiding researchers to focus future clinical studies on specific unanswered questions. The results of the present meta-analysis confirm that research on probiotics and NEC is on the right track, but also suggest that there are several unanswered questions which should be addressed before radically changing clinical practice. Our data highlight the need for further, well-designed studies aimed at clarifying the specific effect of probiotics in high-risk populations (i.e., ELBWs, IUGRs) and at addressing the choice of the most effective probiotic product, at the proper dose and duration of supplementation. For this reason, we encourage, for future studies, the publication of study protocols detailing study population and characteristics of the intervention, in order to narrow probiotic research to the most promising strains or combination of strains and to the most vulnerable populations, thus allowing a confirmative individual patient data analysis.
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